


G. methylene (2*S*,5*R*,6*R*)-6-[[[(2*R*)-[[[(2*R*)-amino-phenylacetyl]amino][(4*S*)-4-[[[(2*S*,5*R*)-3,3-dimethyl-4,4,7-trioxo-4λ<sup>6</sup>-thia-1-azabicyclo[3.2.0]hept-2-yl]carbonyl]oxy]methoxy]carbonyl]-5,5-dimethylthiazolidin-2-yl]acetyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (2*S*,5*R*)-3,3-dimethyl-4,4,7-trioxo-4λ<sup>6</sup>-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate (sultamicillin dimer).

01/2008:1573

## SUMATRIPTAN SUCCINATE

### Sumatriptani succinas



C<sub>18</sub>H<sub>27</sub>N<sub>3</sub>O<sub>6</sub>S  
[103628-48-4]

M<sub>r</sub> 413.5

#### DEFINITION

[3-[2-(Dimethylamino)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulphonamide hydrogen butanedioate.

*Content*: 97.5 per cent to 102.0 per cent (anhydrous substance).

#### CHARACTERS

*Appearance*: white or almost white powder.

*Solubility*: freely soluble in water, sparingly soluble in methanol, practically insoluble in methylene chloride.

#### IDENTIFICATION

Infrared absorption spectrophotometry (2.2.24).

*Preparation*: discs.

*Comparison*: sumatriptan succinate CRS.

#### TESTS

**Solution S**. Dissolve 1.0 g in carbon dioxide-free water *R* and dilute to 25.0 ml with the same solvent.

**pH** (2.2.3): 4.5 to 5.3.

Dilute 2.5 ml of solution S to 10 ml with carbon dioxide-free water *R*.

**Absorbance** (2.2.25): maximum 0.10, measured at 440 nm on solution S.

**Impurities A and H**. Liquid chromatography (2.2.29).

*Test solution*. Dissolve 30.0 mg of the substance to be examined in the mobile phase and dilute to 10.0 ml with the mobile phase.

*Reference solution (a)*. Dilute 1.0 ml of the test solution to 100.0 ml with the mobile phase. Dilute 1.0 ml of this solution to 10.0 ml with the mobile phase.

*Reference solution (b)*. Dissolve the contents of a vial of sumatriptan for system suitability CRS (containing impurities A and H) in the mobile phase and dilute to 1 ml with the mobile phase.

*Column*:

- size:  $l = 0.25$  m,  $\varnothing = 4.6$  mm;
- stationary phase: silica gel for chromatography *R* (5 μm).

*Mobile phase*: mix 10 volumes of a 771 g/l solution of ammonium acetate *R* and 90 volumes of methanol *R*.

*Flow rate*: 2.0 ml/min.

*Detection*: spectrophotometer at 282 nm.

*Injection*: 20 μl.

*Run time*: 5 times the retention time of sumatriptan.

*System suitability*: reference solution (b):

- resolution: minimum 1.5 between the peaks due to sumatriptan and impurity A;
- the chromatogram is similar to the chromatogram supplied with sumatriptan for system suitability CRS.

*Limits*:

- impurity A: not more than 6 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.6 per cent);
- impurity H: not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.3 per cent).

**Related substances**. Liquid chromatography (2.2.29).

*Solution A*. Dissolve 2.925 g of sodium dihydrogen phosphate *R* in 600 ml of water *R*, adjust to pH 6.5 with strong sodium hydroxide solution *R*, dilute to 750 ml with water *R*, add 250 ml of acetonitrile *R* and mix.

*Test solution (a)*. Dissolve 30.0 mg of the substance to be examined in the mobile phase and dilute to 10.0 ml with the mobile phase.

*Test solution (b)*. Dissolve 15.0 mg of the substance to be examined in solution A and dilute to 100.0 ml with solution A.

*Reference solution (a)*. Dilute 1.0 ml of test solution (a) to 100.0 ml with the mobile phase. Dilute 1.0 ml of this solution to 10.0 ml with the mobile phase.

*Reference solution (b)*. Dissolve the contents of a vial of sumatriptan impurity mixture CRS (containing impurities B, C, D and E) in the mobile phase and dilute to 1 ml with the mobile phase.

*Reference solution (c)*. Dissolve 15.0 mg of sumatriptan succinate CRS in solution A and dilute to 100.0 ml with solution A.

*Column*:

- size:  $l = 0.25$  m,  $\varnothing = 4$  mm;
- stationary phase: octadecylsilyl silica gel for chromatography *R* (5 μm).

*Mobile phase*: mix 25 volumes of acetonitrile *R* with 75 volumes of a solution prepared as follows: dissolve 0.970 g of dibutylamine *R*, 0.735 g of phosphoric acid *R*

and 2.93 g of *sodium dihydrogen phosphate R* in 750 ml of *water R*, adjust to pH 6.5 with *strong sodium hydroxide solution R* and dilute to 1000 ml with *water R*.

*Flow rate*: 1.5 ml/min.

*Detection*: spectrophotometer at 282 nm.

*Injection*: 10 µl of test solution (a) and reference solutions (a) and (b).

*Run time*: 4 times the retention time of sumatriptan.

*Identification of impurities*: use the chromatogram obtained with reference solution (b) and the chromatogram supplied with *sumatriptan impurity mixture CRS* to identify the peaks due to impurities B, C, D and E.

*System suitability*: reference solution (b):

- *resolution*: minimum 1.5 between the peaks due to sumatriptan and impurity C;
- the chromatogram shows 5 clearly separated peaks.

*Limits*:

- *impurities B, C, D*: for each impurity, not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent);
- *impurity E*: not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.1 per cent);
- *unspecified impurities*: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (a) (0.10 per cent);
- *total*: not more than 6 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.6 per cent);
- *disregard limit*: 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

**Water** (2.5.12): maximum 1.0 per cent, determined on 0.500 g.

**Sulphated ash** (2.4.14): maximum 0.1 per cent, determined on 1.0 g.

## ASSAY

Liquid chromatography (2.2.29) as described in the test for related substances with the following modification.

*Injection*: test solution (b) and reference solution (c).

Calculate the percentage content of  $C_{18}H_{27}N_3O_6S$  from the declared content of *sumatriptan succinate CRS*.


## STORAGE

Protected from light.


## IMPURITIES

*Specified impurities*: A, B, C, D, E, H.

*Other detectable impurities* (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph *Substances for pharmaceutical use* (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. *Control of impurities in substances for pharmaceutical use*): F, G.




A. [3-[2-(dimethylamino)ethyl]-2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1H-indol-5-yl]-N-methylmethanesulphonamide,




B. R1 = R2 = H: *N*-methyl[3-[2-(methylamino)ethyl]-1H-indol-5-yl]methanesulphonamide,


C. R1 = CH<sub>2</sub>-OH, R2 = CH<sub>3</sub>: [3-[2-(dimethylamino)ethyl]-1-(hydroxymethyl)-1H-indol-5-yl]-*N*-methylmethanesulphonamide,



D. *N,N*-dimethyl-2-[5-[(methylsulphamoyl)methyl]-1H-indol-3-yl]ethanamine *N*-oxide,




E. [3-(2-aminoethyl)-1H-indol-5-yl]-*N*-methylmethanesulphonamide,



F. R = H: *N*-methyl(2,3,4,9-tetrahydro-1H-pyrido[3,4-*b*]indol-6-yl)methanesulphonamide,

G. R = CH<sub>3</sub>: *N*-methyl(2-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-*b*]indol-6-yl)methanesulphonamide,



H. [3-[2-(dimethylamino)ethyl]-1-[[3-[2-(dimethylamino)ethyl]-1*H*-indol-5-yl]methyl]-1*H*-indol-5-yl]-*N*-methylmethanesulphonamide.

01/2008:1371

## SUNFLOWER OIL, REFINED

### *Helianthi annui oleum raffinatum*

#### DEFINITION

Sunflower oil is the fatty oil obtained from the seeds of *Helianthus annuus* L. by mechanical expression or by extraction. It is then refined. A suitable antioxidant may be added.

#### CHARACTERS

A clear, light yellow liquid, practically insoluble in water and in alcohol, miscible with light petroleum (bp: 40 °C to 60 °C).

It has a relative density of about 0.921 and a refractive index of about 1.474.

#### IDENTIFICATION

Carry out the identification of fatty oils by thin-layer chromatography (2.3.2). The chromatogram obtained is similar to the typical chromatogram for sunflower oil.

#### TESTS

**Acid value** (2.5.1). Not more than 0.5, determined on 10.0 g.

**Peroxide value** (2.5.5). Not more than 10.0.

**Unsaponifiable matter** (2.5.7). Not more than 1.5 per cent, determined on 5.0 g.

**Alkaline impurities** (2.4.19). It complies with the test for alkaline impurities in fatty oils.

**Composition of fatty acids** (2.4.22, Method A). The fatty-acid fraction of the oil has the following composition:

- *palmitic acid*: 4.0 per cent to 9.0 per cent,
- *stearic acid*: 1.0 per cent to 7.0 per cent,
- *oleic acid*: 14.0 per cent to 40.0 per cent,
- *linoleic acid*: 48.0 per cent to 74.0 per cent.

#### STORAGE


Store in an airtight, well-filled container, protected from light.

#### LABELLING

The label states whether the oil is obtained by mechanical expression or by extraction.

## SUXAMETHONIUM CHLORIDE

### Suxamethonii chloridum



$C_{14}H_{30}Cl_2N_2O_4 \cdot 2H_2O$   
[6101-15-1]

$M_r$  397.3

#### DEFINITION

Suxamethonium chloride contains not less than 98.0 per cent and not more than the equivalent of 102.0 per cent of 2,2'-[butanedioylbis(oxy)]bis(*N,N,N*-trimethylethanaminium) dichloride, calculated with reference to the anhydrous substance.

#### CHARACTERS

A white or almost white, crystalline powder, hygroscopic, freely soluble in water, slightly soluble in alcohol.

It melts at about 160 °C, determined without previous drying.

#### IDENTIFICATION

*First identification: A, D.*

*Second identification: B, C, D.*

- A. Examine by infrared absorption spectrophotometry (2.2.24), comparing with the spectrum obtained with *suxamethonium chloride CRS*. Examine the substances prepared as discs.
- B. To 1 ml of solution S (see Tests) add 9 ml of *water R*, 10 ml of *dilute sulphuric acid R* and 30 ml of *ammonium reineckate solution R*. A pink precipitate is formed. Allow to stand for 30 min, filter, wash with *water R*, with *alcohol R* and then with *ether R* and dry at 80 °C. The melting point (2.2.14) of the precipitate is 180 °C to 185 °C.
- C. Dissolve about 25 mg in 1 ml of *water R* and add 0.1 ml of a 10 g/l solution of *cobalt chloride R* and 0.1 ml of *potassium ferrocyanide solution R*. A green colour is produced.
- D. About 20 mg gives reaction (a) of chlorides (2.3.1).

#### TESTS

**Solution S.** Dissolve 1.0 g in *carbon dioxide-free water R* and dilute to 20 ml with the same solvent.

**Appearance of solution.** Solution S is clear (2.2.1). Dilute 4 ml of solution S to 10 ml with *water R*. The solution is colourless (2.2.2, Method II).

**pH** (2.2.3). Dilute 1 ml of solution S to 10 ml with *carbon dioxide-free water R*. The pH of the solution is 4.0 to 5.0.

**Choline chloride.** Examine by thin-layer chromatography (2.2.27), using *cellulose for chromatography R1* as the coating substance.

**Test solution.** Dissolve 0.4 g of the substance to be examined in *methanol R* and dilute to 10 ml with the same solvent.

**Reference solution.** Dissolve 0.4 g of *suxamethonium chloride CRS* and 2 mg of *choline chloride R* in *methanol R* and dilute to 10 ml with the same solvent.